Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.19 USD

41.19
2,363,250

+0.87 (2.16%)

Updated Aug 13, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novartis (NVS) Receives EC Approval for Neulasta Biosimilar

by Zacks Equity Research

Novartis (NVS) obtains EC approval for Ziextenzo, the biosimilar of Amgen's Neulasta.

What Makes GlaxoSmithKline (GSK) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does GlaxoSmithKline (GSK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Glaxo's Horlicks Sale Bid Heats Up, Nestle, Unilever Close In

by Zacks Equity Research

Per a Financial Times report, Glaxo (GSK) is in exclusive talks with Unilever to sell its Horlicks brand in India. Another report in an India-based newspaper says Nestle is close to buying Horlicks.

Astrazeneca's Fasenra Gets Orphan Drug for Autoimmune Disease

by Zacks Equity Research

AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.

3 Reasons Why Glaxo (GSK) Stock is Up This Year So Far

by Zacks Equity Research

Glaxo's (GSK) shares have outperformed the industry this year. Here are some reasons for the same.

Glaxo (GSK) and J&J's HIV Drug Juluca Gets Approval in Japan

by Zacks Equity Research

GlaxoSmithKline (GSK) along with partner J&J gains approval for two-drug HIV regimen Juluca from the Japanese Ministry of Health, Labour and Welfare to benefit patients in the country.

Glaxo Inks Marketing Deal for Anaemia Candidate in Japan

by Zacks Equity Research

GlaxoSmithKline (GSK) signs a collaboration contract with Japan's Kyowa Hakko Kirin for future commercialization of daprodustat in Japan.

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, AbbVie, J&J, Glaxo and AstraZeneca

Gilead's HIV Franchise, CAR T Therapy Likely to Propel Growth

by Zacks Equity Research

Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?

by Zacks Equity Research

Let???s see if GlaxoSmithKline plc (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

Pharma Stock Roundup: Cancer Approvals for PFE & ABBV, CHMP Nod for Several Drugs

by Zacks Equity Research

FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs

FDA Accepts Allergan's (AGN) sNDA for Anti-Infective Avycaz

by Zacks Equity Research

The FDA accepts Allergan's (AGN) sNDA for the label expansion of its antibacterial medicine, Avycaz, to treat cUTI and cIAI in pediatric patients.

Gilead's Vemlidy Gets Approval in China for HBV Infection

by Zacks Equity Research

Gilead (GILD) obtains approval for Vemlidy in China for the treatment of chronic hepatitis B in adults and adolescents.

Glaxo Seeks Label Expansion of Nucala in Pediatric Patients

by Zacks Equity Research

Glaxo (GSK) submits sBLA to the FDA seeking label expansion of its asthma drug, Nucala, in pediatric patients in the United States.

Novartis (NVS) Gets FDA Nod for Label Expansion of Promacta

by Zacks Equity Research

Novartis (NVS) obtains FDA approval for the label expansion of Promacta. The CHMP also issues a positive opinion for the label expansion of Kisqali.

Merck's Keytruda Improves Survival in Esophageal Cancer Study

by Zacks Equity Research

Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.

Has GlaxoSmithKline plc (GSK) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (GSK) Outperforming Other Medical Stocks This Year?

Glaxo/Innoviva's Trelegy Ellipta Gets Line Extension in Europe

by Zacks Equity Research

Glaxo (GSK) and Innoviva announce approval of label expansion for COPD drug, Trelegy Ellipta, in Europe to include patients not adequately treated with dual bronchodilation.

Merck's (MRK) Keytruda Gets FDA Approval for Liver Cancer

by Zacks Equity Research

Merck's (MRK) Keytruda gains FDA approval for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib.

Theravance (TBPH) Beats on Q3 Earnings, Inks Deal for Vibativ

by Zacks Equity Research

Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q3. The top line betters estimates.

Mylan (MYL) Earnings Beat, Revenues Miss Estimates in Q3

by Zacks Equity Research

Mylan's (MYL) Q3 revenues lag estimates due to persistent challenges in the North America segment.

Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates

by Zacks Equity Research

Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.

Pharma Stock Roundup: PFE, AGN Q3 Earnings, LLY, NVS Collaboration Deals in Focus

by Zacks Equity Research

Pfizer (PFE) and Allergan (AGN) report third-quarter results. Eli Lilly (LLY), Pfizer and Sanofi (SNY) announce collaboration deals.

Glaxo (GSK) Beats on Q3 Earnings & Sales, Raises '18 View

by Zacks Equity Research

Glaxo (GSK) beats earnings and sales estimates in the third quarter. Strong sales growth of HIV and respiratory portfolio boosts sales while cost control initiatives aid bottom line.

Mylan (MYL) Q3 Earnings: Is a Disappointment in the Cards?

by Zacks Equity Research

Investors will focus on the performance of EpiPen, newly launched biosimilars and other updates from Mylan's (MYL) pipeline, when it reports Q3 results.